The estimated Net Worth of Mark K Oki is at least $501 Тысяча dollars as of 6 November 2018. Mr. Oki owns over 10,000 units of VIVUS stock worth over $4,665 and over the last 9 years he sold VVUS stock worth over $0. In addition, he makes $496,136 as Chief Financial Officer, Senior Vice President и Chief Accounting Officer at VIVUS.
Mark has made over 1 trades of the VIVUS stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of VVUS stock worth $40,700 on 6 November 2018.
The largest trade he's ever made was buying 10,000 units of VIVUS stock on 6 November 2018 worth over $40,700. On average, Mark trades about 714 units every 0 days since 2015. As of 6 November 2018 he still owns at least 10,000 units of VIVUS stock.
You can see the complete history of Mr. Oki stock trades at the bottom of the page.
Mark K. Oki serves as Chief Financial Officer, Senior Vice President, Chief Accounting Officer of the Company. Mr. Oki has served as our Senior Vice President, Chief Financial Officer and Chief Accounting Officer since February 2019. From October 2015 until February 2019, Mr. Oki served as our Chief Financial Officer and Chief Accounting Officer. Prior to this, Mr. Oki held the following positions at Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company: Senior Vice President, Finance and Chief Financial Officer from July 2012 until October 2015, Principal Accounting Officer from May 2010 until October 2015, Principal Financial Officer and Secretary from December 2011 until October 2015, Vice President, Finance and Controller from February 2010 until July 2012 and Controller from April 2006 until February 2010. From June 2001 until April 2006, he served as the Controller of Pharmacyclics, Inc., a publicly traded development stage pharmaceutical company. From 1998 until 2001, Mr. Oki held several positions at Incyte Genomics, Inc., now Incyte Corporation, a publicly traded company, including most recently as Assistant Controller. From 1992 until 1997, he held several positions at Deloitte & Touche LLP, a public accounting firm. Mr. Oki holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University.
As the Chief Financial Officer, Senior Vice President и Chief Accounting Officer of VIVUS, the total compensation of Mark Oki at VIVUS is $496,136. There are 3 executives at VIVUS getting paid more, with John Amos having the highest compensation of $873,894.
Mark Oki is 51, he's been the Chief Financial Officer, Senior Vice President и Chief Accounting Officer of VIVUS since 2019. There are 8 older and 1 younger executives at VIVUS. The oldest executive at VIVUS, Inc. is Edward Kangas, 75, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.
Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner и Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
VIVUS executives and other stock owners filed with the SEC include: